The histone deacetylase inhibitor, MS-275 (Entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases

Current Cancer Drug Targets

Volumn 13, Issue 4, 2013, Pages 411-422

  Rao Bindal, Krithi ^a   Koshkina, Nadezhda V ^a   Stewart, John ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

c FLIP; Entinostat; Fas; FasL; Histone deacetylase inhibitors; MS 275; Osteosarcoma

Indexed keywords

CASPASE 8; ENTINOSTAT; FAS LIGAND; FLICE INHIBITORY PROTEIN; HISTONE H3; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIZATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MOUSE; NICK END LABELING; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SHORT TANDEM REPEAT; TUMOR REGRESSION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; BONE NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL PROLIFERATION; FAS LIGAND PROTEIN; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, NUDE; OSTEOSARCOMA; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84878645229     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313040005     Document Type: Article

References (39)

1. Hawkins, D. S.; Arndt, C. A. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003, 98 (11), 2447-2456.
2. Eilber, F.; Giuliano, A.; Eckardt, J.; Patterson, K.; Moseley, S.; Goodnight, J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J. Clin. Oncol. 1987, 5 (1), 21-6.
3. Koshkina, N. V.; Khanna, C.; Mendoza, A.; Guan, H.; DeLauter, L.; Kleinerman, E. S. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol. Cancer Res. 2007, 5 (10), 991-999.
4. Gordon, N.; Arndt, C. A.; Hawkins, D. S.; Doherty, D. K.; Inwards, C. Y.; Munsell, M. F.; Stewart, J.; Koshkina, N. V.; Kleinerman, E. S. Fas expression in lung metastasis from osteosarcoma patients. J. Pediatr. Hematol. Oncol. 2005, 27 (11), 611-615.
5. Gordon, N.; Kleinerman, E. S. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat. Res. 2009, 152, 497-508.
6. Gordon, N.; Koshkina, N. V.; Jia, S. F.; Khanna, C.; Mendoza, A.; Worth, L. L.; Kleinerman, E. S. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin. Cancer Res. 2007, 13 (15 Pt 1), 4503-4510.
7. Duan, X.; Jia, S. F.; Koshkina, N.; Kleinerman, E. S. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 2006, 106 (6), 1382-1388.
8. Zhou, Z.; Lafleur, E. A.; Koshkina, N. V.; Worth, L. L.; Lester, M. S.; Kleinerman, E. S. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol. Cancer Res. 2005, 3 (12), 685-691.
9. Jia, S. F.; Worth, L. L.; Densmore, C. L.; Xu, B.; Duan, X.; Kleinerman, E. S. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin. Cancer Res. 2003, 9 (9), 3462-3468.
10. Jia, S. F.; Worth, L. L.; Densmore, C. L.; Xu, B.; Zhou, Z.; Kleinerman, E. S. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 2002, 9 (3), 260-266.
11. Ashkenazi, A.; Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 1999, 11 (2), 255-260.
12. Bullani, R. R.; Huard, B.; Viard-Leveugle, I.; Byers, H. R.; Irmler, M.; Saurat, J. H.; Tschopp, J.; French, L. E. Selective expression of FLIP in malignant melanocytic skin lesions. J. Invest. Dermatol. 2001, 117 (2), 360-364.
13. de Hooge, A. S.; Berghuis, D.; Santos, S. J.; Mooiman, E.; Romeo, S.; Kummer, J. A.; Egeler, R. M.; van Tol, M. J.; Melief, C. J.; Hogendoorn, P. C.; Lankester, A. C. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin. Cancer Res. 2007, 13 (1), 206-214.
14. Elnemr, A.; Ohta, T.; Yachie, A.; Kayahara, M.; Kitagawa, H.; Fujimura, T.; Ninomiya, I.; Fushida, S.; Nishimura, G. I.; Shimizu, K.; Miwa, K. Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int. J. Oncol. 2001, 18 (2), 311-316.
15. Griffith, T. S.; Chin, W. A.; Jackson, G. C.; Lynch, D. H.; Kubin, M. Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 1998, 161 (6), 2833-2840.
16. Hernandez, A.; Wang, Q. D.; Schwartz, S. A.; Evers, B. M. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J. Gastrointest. Surg. 2001, 5 (1), 56-65.
17. Korkolopoulou, P.; Goudopoulou, A.; Voutsinas, G.; Thomas-Tsagli, E.; Kapralos, P.; Patsouris, E.; Saetta, A. A. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004, 63 (6), 1198-1204.
18. Nam, S. Y.; Jung, G. A.; Hur, G. C.; Chung, H. Y.; Kim, W. H.; Seol, D. W.; Lee, B. L. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci. 2003, 94 (12), 1066-1073.
19. Glick, R. D.; Swendeman, S. L.; Coffey, D. C.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.; La Quaglia, M. P. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 1999, 59 (17), 4392-4399.
20. Klisovic, D. D.; Katz, S. E.; Effron, D.; Klisovic, M. I.; Wickham, J.; Parthun, M. R.; Guimond, M.; Marcucci, G. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest. Ophthalmol. Vis. Sci. 2003, 44 (6), 2390-2398.
21. Kwon, S. H.; Ahn, S. H.; Kim, Y. K.; Bae, G. U.; Yoon, J. W.; Hong, S.; Lee, H. Y.; Lee, Y. W.; Lee, H. W.; Han, J. W. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 2002, 277 (3), 2073-2080.
22. Watanabe, K.; Okamoto, K.; Yonehara, S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 2005, 12 (1), 10-18.
23. Rivera-Del Valle, N.; Gao, S.; Miller, C. P.; Fulbright, J.; Gonzales, C.; Sirisawad, M.; Steggerda, S.; Wheler, J.; Balasubramanian, S.; Chandra, J. PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. Int. J. Cell Biol. 2010, 2010, 207-420.
24. Aron, J. L.; Parthun, M. R.; Marcucci, G.; Kitada, S.; Mone, A. P.; Davis, M. E.; Shen, T.; Murphy, T.; Wickham, J.; Kanakry, C.; Lucas, D. M.; Reed, J. C.; Grever, M. R.; Byrd, J. C. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003, 102 (2), 652-658.
25. Lucas, D. M.; Davis, M. E.; Parthun, M. R.; Mone, A. P.; Kitada, S.; Cunningham, K. D.; Flax, E. L.; Wickham, J.; Reed, J. C.; Byrd, J. C.; Grever, M. R. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004, 18 (7), 1207-1214.
26. Jaboin, J.; Wild, J.; Hamidi, H.; Khanna, C.; Kim, C. J.; Robey, R.; Bates, S. E.; Thiele, C. J. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 2002, 62 (21), 6108-6115.
27. Coffey, D. C.; Kutko, M. C.; Glick, R. D.; Butler, L. M.; Heller, G.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.; La Quaglia, M. P. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 2001, 61 (9), 3591-3594.
28. Strauss, S.J.; Ng, T.; Mendoza-Naranjo, A.; Whelen, J.; Sorensen, P.H. Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma. Oncologist 2010, 15 (6), 627-635.
29. Koshkina, N. V.; Kleinerman, E. S. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int. J. Cancer 2005, 116 (3), 458-463.
30. Koshkina, N. V.; Rao-Bindal, K.; Kleinerman, E. S. Effect of the histone deacetylase inhibitor SNDX-275 on fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 2011, 117 (15), 3457-3467.
31. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J. L.; Schroter, M.; Burns, K.; Mattmann, C.; Rimoldi, D.; French, L. E.; Tschopp, J. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388 (6638), 190-195.
32. Bijangi-Vishehsaraei, K.; Saadatzadeh, M. R.; Huang, S.; Murphy, M. P.; Safa, A. R. 4-(4-Chloro-2-methylphenoxy)-Nhydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells. Mol. Cell Biochem. 2010, 342 (1-2), 133-142.
33. Guo, F.; Sigua, C.; Tao, J.; Bali, P.; George, P.; Li, Y.; Wittmann, S.; Moscinski, L.; Atadja, P.; Bhalla, K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004, 64 (7), 2580-2589.
34. Kauh, J.; Fan, S.; Xia, M.; Yue, P.; Yang, L.; Khuri, F. R.; Sun, S. Y. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 2010, 5 (4), e10376.
35. Schuchmann, M.; Schulze-Bergkamen, H.; Fleischer, B.; Schattenberg, J. M.; Siebler, J.; Weinmann, A.; Teufel, A.; Worns, M.; Fischer, T.; Strand, S.; Lohse, A. W.; Galle, P. R. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95-and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol. Rep. 2006, 15 (1), 227-230.
36. Hartlapp, I.; Pallasch, C.; Weibert, G.; Kemkers, A.; Hummel, M.; Re, D. Depsipeptide induces cell death in Hodgkin lymphomaderived cell lines. Leuk. Res. 2009, 33 (7), 929-936.
37. Simonini, M. V.; Camargo, L. M.; Dong, E.; Maloku, E.; Veldic, M.; Costa, E.; Guidotti, A. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl. Acad. Sci. USA 2006, 103 (5), 1587-1592.
38. Marks, P. A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 2010, 19 (9), 1049-1066.
39. Hoffman, R. The multiple uses of flourescent proteins to visualize cancer in vivo. Nat. Rev. Cancer 2005, 5 (10), 796-806.